Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | MDH1 | P40925 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.74 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18326508 | 0.90 | ADRA2A (0.75) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL14440008 | 0.89 | ADRA2A (0.73) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL8924496 | 0.88 | ADRA2A (0.58) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL12423824 | 0.86 | OPRM1 (0.70) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29602259 | 0.85 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL34420 | 0.85 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29714124 | 0.85 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL30803764 | 0.85 | ADRA2A (1.00) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL29683747 | 0.85 | ADRA2A (0.75) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Delavirdine SCHEMBL29585604 | 0.85 | ADRA2A (0.98) | ADRA2AADORA3CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421204-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421204-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-9226970-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226970-B2 | Oligomer modified diaromatic substituted compounds | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011103559-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-5599930-A | Substituted indoles as anti-AIDS pharmaceuticals | THE UPJOHN COMPANY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0594702-B1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS | UPJOHN CO (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5563142-A | INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5489593-A | Anti-aids piperazines | THE UPJOHN COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0594702-A1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS. | UPJOHN CO (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993001181-A1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS | THE UPJOHN COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040961-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | PCNA, DNPEP, POLI | ADRA2A 3028/4885ADORA3 2121/4885CHRM1 2929/4885 |
| US-20160143904-A1 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS | HLA-DRB1, NOD2, DCX | ADRA2A 1953/4885ADORA3 923/4885CHRM1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.